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Drug resistance in bacterial infections and cancers
constitutes a major threat to human health. Treat-
ments often include several interacting drugs, but
even potent therapies can become ineffective in
resistant mutants. Here, we simplify the picture of
drug resistance by identifying scaling laws that unify
themultidrug responses of drug-sensitive and -resis-
tant cells. On the basis of these scaling relationships,
we are able to infer the two-drug response of resis-
tant mutants in previously unsampled regions of
dosage space in clinically relevant microbes such
as E. coli, E. faecalis, S. aureus, and S. cerevisiae
as well as human non-small-cell lung cancer, mela-
noma, and breast cancer stem cells. Importantly,
we find that scaling relations also apply across evolu-
tionarily close strains. Finally, scaling allows one to
rapidly identify new drug combinations and predict
potent dosage regimes for targeting resistant
mutants without any prior mechanistic knowledge
about the specific resistance mechanism.INTRODUCTION
Treatment strategies for infectious diseases and cancers often
involve multiple drugs that must be combined, adapted, and
refined to target evolving cell populations. Multidrug therapies
can be difficult to design because drugs often interact, making
their combined effects larger or smaller than expected from their
individual effects (Bliss, 1956; Fitzgerald et al., 2006; Greco et al.,
1995; Keith et al., 2005; Leha´r et al., 2008; Loewe, 1953). Further-
more, well-developed multidrug treatments can be thwarted by
the emergence of multidrug resistance, which arises in both
bacterial infections and cancer, and represents a growing public
health threat (Levy and Marshall, 2004). For example, potent
drug regimens designed to target a particular cancer may be
rendered ineffective by the rapid evolution of drug resistanceCe(Garrett and Arteaga, 2011; Glickman and Sawyers, 2012;
Poulikakos and Rosen, 2011). In addition, drugs may interact
differently in each new resistant mutant, making the molecular
characterization of resistance a time-consuming and at times
untenable goal. Because of the rapidly increasing number of
multidrug-resistant mutants, there is a significant need for new
strategies to characterize and refine drug regimens in hopes of
mitigating the effects of resistance.
Scaling laws can offer a complementary approach for simpli-
fying the picture of multidrug-resistance without relying on highly
time- and resource-consuming molecular studies. These laws,
which can be surprisingly simple, are often based on symmetry
arguments rather than system-specific microscopic details.
Scaling is powerful because it offers a quantitative unifying
framework for systems that appear, on the surface, to be very
different. For example, allometric scaling laws (Shoval et al.,
2012) connect anatomical and physiological features, such as
body mass and metabolism, across a wide range of organisms.
Similar relations have contributed to our understanding of
phenotypic variability in populations of bacteria (Balaban et al.,
2004) and eukaryotic immune cells (Feinerman et al., 2008), the
fluctuation-response relationship in bacterial chemotaxis (Park
et al., 2010), the structural properties of metabolic networks
(Jeong et al., 2000), growth and gene expression in populations
of Escherichia coli (Scott et al., 2010), and epistatic interactions
between genes in yeast (Velenich and Gore, 2013). Motivated by
the success of scaling laws across disciplines, we set out to
identify similar principles that could unify the description of
drug interactions in sensitive and resistant cells. The discovery
of such scaling relations could provide an approach for system-
atically adaptingmultidrug treatments to effectively combat drug
resistance, even before the molecular mechanisms have been
fully elucidated.RESULTS
Drug Interactions Can Change following Acquisition
of Resistance
We first asked how acquired drug resistance affects the inter-
actions between two drugs observed initially in wild-type (WT)ll Reports 6, 1073–1084, March 27, 2014 ª2014 The Authors 1073
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Figure 1. Resistance that Either Alters or Conserves Interactions between Drugs in Prokaryotic and Eukaryotic Cells
Heatmaps quantify the drug interaction and classify it as synergistic or antagonistic across a range of active concentrations for both WT and mutant cells. To
quantify the drug interaction at each point on the response surface, we define the interaction parameter I = log2(g12  g1 g2 + 1), which is positive (blue) for
antagonistic, negative (red) for synergistic interactions (Bollenbach and Kishony, 2011), and zero when there is no interaction (g12 = g1 g2, consistent with Bliss
independence). In addition to modifying the resistance of cells to one or more drugs, resistance events can sometimes modify the interactions between drug
pairs. See Figure S1 for an alternative quantification of drug interactions. We note that because themutants in this study are resistant to at least one drug, wemust
use higher drug concentrations for the mutant cells to obtain growth reduction. However, we estimated the drug interactions over concentration ranges that yield
approximately similar growth reductions in mutant and WT cells (Figure S1). Drug concentrations are given in units of mg/ml unless otherwise noted.
(A) Gefitinib (Gef) resistance in NSCLC cells changes the interaction between 17-AAG and gefitinib from strongly antagonistic (suppressive) to synergistic.
[17-AAG] and [gefitinib] are in units of nM and mM, respectively.
(B) Chloramphenicol (Cm) resistance inE. coli changes the interaction between salicylate (Sal) andCm from strongly antagonistic (suppressive) to additive/weakly
synergistic.
(C) Cm and ciprofloxacin (Cip) resistance in E. coli weakens the strongly antagonistic (suppressive) interaction between Cm and Cip, but does not eliminate the
antagonism. [Cip] is in units of ng/ml.
(D) Daptomycin (Dap) resistance in E. faecalis reduces the strongly synergistic interaction between ampicillin and Dap.
(E) Erythromycin (Ery) and doxycycline (Dox) resistance in E. coli increases the synergistic interaction between the two drugs.
(F) Norfloxacin (Nor) resistance in S. aureus does not change the interaction between Cm and Nor.drug-sensitive cells. To answer this question, we measured the
population growth of a wide range of organisms, including bac-
teria and human cancer cells, in response to drug pairs (Supple-
mental Experimental Procedures; Tables S1–S3). We then
quantified the nature of the drug interaction, i.e., synergy or
antagonism, in both WT and resistant cells using two standard
pharmacology approaches (Figures 1 and S1). Interestingly, we
find that resistance can alter not only the individual drug1074 Cell Reports 6, 1073–1084, March 27, 2014 ª2014 The Authorsefficacies but also the interactions between drugs. That is, two
drugs can interact quite differently depending on whether they
are applied to drug-resistant mutants or drug-sensitive cells (Fig-
ures 1 and S1). For example, the combination of two anticancer
agents, gefitinib and 17-AAG, is antagonistic for most dosages in
EGFR mutant non-small-cell lung cancer (NSCLC) cells, making
it an unlikely a priori choice for therapy (Figure 1A). However, the
same drug pair becomes synergistic for most dosages (Xu et al.,
2012) in a gefitinib-resistant mutant (Engelman et al., 2007; Fig-
ure 1A). On the other hand, in E. coli, the antagonism between
some drug pairs is eliminated (Figure 1B) or reduced (Figure 1C)
in antibiotic-resistant mutants, but the interactions do not
become synergistic. A similar decrease in the interactions
between antibiotics occurs in vancomycin-resistant Entero-
coccus faecalis (Palmer et al., 2011), where the synergy (Rand
and Houck, 2004) in the combination of daptomycin and ampi-
cillin is reduced in certain daptomycin-resistant mutants (Fig-
ure 1D). By contrast, in E. coli exposed to the weakly synergistic
combination of doxycycline (Dox) and erythromycin (Ery), the
drug pair becomes increasingly synergistic in some multidrug-
resistant mutants (Figure 1E). We also observe cases in which
the drug interactions are not changed by resistance events.
For example, the antibiotics chloramphenicol (Cm) and norfloxa-
cin (Nor) show approximately the same level of antagonism in
Staphylococcus aureus cells and Nor-resistant mutants. In this
case, the mutation reduces the effective concentration at which
Nor becomes toxic, but otherwise does not modify the shape of
the cell’s two-drug response surface. Similar results have been
reported for some mutations in E. coli (Chait et al., 2007). In
summary, we find that resistance can alter drug interactions in
multiple different ways, and there is no obvious relationship
between the interactions observed in sensitive cells and those
in resistant mutants.
ASimpleModel CanDescribe aWideRange of Two-Drug
Response Surfaces
To establish a relationship between drug interactions before
and after the acquisition of resistance, we constructed a sim-
ple model to quantitatively characterize growth response
surfaces after exposure to two drugs (separately or in combi-
nation). Response surfaces are commonly used to quantify
and classify the interactions between two drugs based
on measurements of cell proliferation (Fitzgerald et al., 2006;
Greco et al., 1995; Leha´r et al., 2007, 2008). However, most
models apply to only a subset of all measured response sur-
faces because they are based on simplified enzyme kinetics
or are specific to particular drug classes and particular intra-
cellular pathways (Fitzgerald et al., 2006; Greco et al., 1995;
Leha´r et al., 2007, 2008). To account for different types of
response surfaces, we used a model of the following multipli-
cative form:
g1;2 = g1ðD1Þg2ðD2effÞ (Equation 1)
where g1,2 is the growth in the presence of drugs 1 and 2
together, g1 is the growth as a function of drug 1 alone, and g2
is the growth as a function of drug 2 alone. D1 is the concentra-
tion of drug 1, and D2eff is the effective concentration of drug 2,
which accounts for interactions between the drugs. Changing
the concentration D2 into D2eff formally captures the interaction
between the two drugs by allowing the presence of one drug
(D1) to modify the effective concentration and hence the toxicity
of the other drug (D2) according to
D2eff =D2ð1+CðD1ÞÞ-1; (Equation 2)CeNote that D2eff is equal to the concentration D2 modified by a
factor (1 + C(D1))
1 that depends only on D1. This dependence
is governed by the function C(D1), which we call the two-drug
toxicity function (see Supplemental Results). The specific defini-
tion of this factor is empirical and was chosen by analogy to
simple efflux-mediated drug interactions (Wood and Cluzel,
2012). The function C(D1) will prove essential for establishing
scaling relationships between WT and mutant cells. Importantly,
Equations 1 and 2 allow us to decompose two-drug response
surfaces into three simpler, one-dimensional ‘‘basis functions’’:
g1(D1), g2(D2), and C(D1).
We first verified that this model is sufficiently general to
describe, with a minimal number of parameters, all experimen-
tally observed response surfaces. Figure 2A shows a typical
example of a response surface, in this case for E. coli, in the
presence of the antibiotics Cm and ciprofloxacin (Cip) (for exper-
imental details, see Supplemental Experimental Procedures).
Strongly antagonistic behavior between these drug classes
has been linked with a suboptimal ratio of protein to DNA in
the cell (Bollenbach et al., 2009). Using the measured two-
dimensional response surface, we first extracted the one-drug
toxicity functions (g1 and g2) and then determined the two-drug
toxicity function C(D1) empirically from the data. Specifically,
we fit the response surface data using the two latter equations
and an empirical parameterization for C(D1). We selected the
best parameterization of C(D1) among a set of 11 possibilities
using Akaike Information Criteria, a robust model selection
technique (Supplemental Results). Together with Equation 1,
these three functions (g1, g2, and C(D1)) determine the bacterial
growth response surface for any concentration of the two drugs
(Figure 2, right).
The model provides a similarly good description for all of the
19 additional drug pairs tested (Supplemental Results; Table
S5), spanning a wide range of response surfaces and yielding
C(D1) functions with many different shapes (Figure 2B). In
some mechanistically tractable cases, the two-drug toxicity
function is constrained by the intracellular molecular pathways
underlying the single-drug and multidrug responses (Supple-
mental Results; Figure S2). For example, in themultiple antibiotic
resistance (MAR) system, C(D1) is proportional to the activity of
the mar promoter (Figure S2B; Wood and Cluzel, 2012). More
generally, the model decomposes two-dimensional response
surfaces into three simpler, empirical functions that do not
require a detailed molecular understanding of the drug interac-
tion or mode of action.
The Decomposition of Response Surfaces into Basis
Functions Reveals Scaling Relationships between
Drug-Sensitive and -Resistant Cells
Next, we exploited the decomposition of response surfaces
into basis functions to search for mathematical relationships
between the multidrug responses of drug-sensitive and -resis-
tant cells. We hypothesized that certain properties of the basis
functions should be conserved when bacteria become drug
resistant. Specifically, we postulated that the effect of resis-
tance could be to (1) rescale the concentration of each drug,
with the scaling factors a1 or a2 being specific to each mutant,
and/or (2) change the interaction between drugs by rescalingll Reports 6, 1073–1084, March 27, 2014 ª2014 The Authors 1075
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Figure 2. Characterization of Bacterial Response to a Pair of Drugs with a Set of Three Unique Basis Functions
(A) Experimental heatmap of growth rate relative to that of untreated cells in response to a pair of drugs (Cm and Cip, left). Red is maximum growth, blue is no
growth. See Supplemental Experimental Procedures for an estimate of uncertainty in growth rate. [Cm] and [Cip] are in units of mg/ml and ng/ml, respectively.
Drug 1 (Cm, middle top), drug 2 (Cip, middle center), and two-drug toxicity functions (C(D1), middle bottom) are shown. The one-drug toxicity functions are
modeled using the Hill form, which is commonly used in pharmacology, where Ki is the concentration of drug i (for i = 1,2) at which the effect is half-maximal (also
known as the IC50), and ni is the Hill coefficient describing the slope of the response. The function C(D1) is an empirically determined function that captures the
effect of drug 1 (Cm) on drug 2 (Cip) (Equation 2). It is fit directly from data and has the following intuitive interpretation: C(D1) = 0 when drug 1 does not alter the
effect of drug 2, C(D1) > 0 indicates antagonistic interaction, and C(D1) < 0 indicates a synergistic interaction. The one-drug toxicity functions along with C(D1)
accurately describe the entire two-dimensional response surface (right). Circles, experimental measurements; solid lines, nonlinear fits to functional forms in (A);
error bars indicate ±1 SE of the growth rate estimate (Supplemental Results). The responses to all 19 drug pairs tested are well described by unidirectional
two-drug toxicity functions. See also Figure S2 and Table S5.
(B) Example two-drug toxicity functions C(D) for six different drug pairs. For example, ‘‘C(D) for Tmp’’ (first panel) describes the effects of Cm on trimethoprim
(Tmp). Concentrations are measured in units of MIC = Ki for each drug. Ofl, ofloxacin; Tet, tetracycline; Ery, erythromycin.the amplitude of the two-drug toxicity function C(D1)
(Equation 2) by a single parameter, a3 (Figure 3). Assumption
1 is consistent with known resistance mechanisms, such as
upregulation of efflux pumps (Wood and Cluzel, 2012), enzy-
matic degradation, and target modification, all of which reduce
the effective intracellular concentrations of a drug (Chait et al.,
2007). Assumption 2 preserves the shape, but not the magni-
tude, of the two-drug toxicity function C(D1). This assumption1076 Cell Reports 6, 1073–1084, March 27, 2014 ª2014 The Authorsstems from the idea that new resistant mutants will not funda-
mentally redefine the strategies that the parent cell has evolved
to cope with the stress of specific drugs. There should exist,
therefore, a hidden symmetry unifying the responses of
drug-sensitive and -resistance cells. Under this assumption,
however, the two-drug response surface can still change
dramatically—for example, from synergistic to antagonistic—
when cells become drug resistant. This change is captured
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Figure 3. Single-Drug Toxicity Functions and Coupling Functions (D2,eff/D2) for Drug-Resistant Mutants Can Be Rescaled to Match Those in
Parental E. coli, E. faecalis, and NSCLC Cells
(A) Single-drug toxicity functions (top left, top center) and two-drug toxicity functions (top right) for 18mutant strains isolated by selection in Cm and Cip at various
doses (Figure S3; Table S3). Each color/marker combination represents a single mutant. Drug concentrations are in units of mg/ml for Cm (323 g/mol) and ng/ml
for Cip (331 g/mol). C(D1) functions are constructed point by point from raw growth data (Supplemental Results).
(B) One-drug toxicity functions (bottom left, bottom center) and two-drug toxicity functions (bottom right) for all mutant strains are simple rescalings of the
corresponding functions in the WT cells (Supplemental Results). A set of three scaling parameters, (a1, a2, a3), provide a set of coordinates that define each
mutant. Specifically, mutant one-drug and two-drug toxicity functions are obtained from those of WT cells by applying the following transformations:
D1/D
0
1 = a1D1
D2/D
0
2 = a2D2
C/C
0
= a3C
where a1, a2, and a3 are scaling parameters that describe the change in resistance to drug 1, the change in resistance to drug 2, and the change in the amplitude of
C(D1), respectively, in the resistantmutant. Solid line, bottom: one-drug toxicity functions (left and center) and two-drug toxicity functions (right) that best describe
the rescaled data.
(C–E) Examples of rescaling the amplitude of C(D1) to demonstrate the scaling relations in drug-sensitive and -resistant cells. Left: C(D1) functions for WT (filled
circles) and drug-resistant (open circles) cells. Right: C(D1) functions for WT (filled circles) and drug-resistant (open circles) cells following a rescaling of the
amplitude by a3. Rescaling of the WT two-drug toxicity (black) Dap C mutant (D; Table S1). Drug concentrations are in units of mg/ml for Cm (323 g/mol),
daptomycin (1619 g/mol), and ampicillin (349 g/mol); ng/ml for Cip (331 g/mol); mM for gefitinib (446 g/mol); and nM for 17-AAG (586 g/mol).
In all panels, error bars indicate ±1 SE of the growth rate estimate for toxicity functions (see Supplemental Results) and ±1 SE of the fitted parameter for two-drug
toxicity functions.entirely by the scaling factor a3. Hypotheses 1 and 2 are further
motivated by results from the well-characterized MAR system
(Wood and Cluzel, 2012) and by numerical toy models (Supple-
mental Results). If the model is accurate, it predicts that simpleCescaling relations establish a quantitative link between the
response surfaces of drug-sensitive and -resistant cells. Impor-
tantly, this scaling approach implies that it may be possible to
predict the full two-drug response of resistant mutants from all Reports 6, 1073–1084, March 27, 2014 ª2014 The Authors 1077
Figure 4. Method for Inferring theResponse
Surfaces of Drug-Resistant Mutants from
the Response Surfaces of WT Cells
The two-drug response surfaces of WT (drug-
sensitive) cells can be used to infer the responses
of drug-resistant mutants. First, one must extract
the three basis functions that describe the WT
surface (Figure 2). Second, one can estimate the
scaling parameters a1, a2, and a3 using a small
number of measurements of the mutant response
(left) and then fully reconstruct the response
surfaces for each mutant (right).small number of measurements when the response of drug-
sensitive cells is known.
To experimentally test the model, we isolated drug-resistant
mutants of E. coli by growing WT cells for 30–60 generations in
various inhibitory concentrations of Cm and Cip either together
or sequentially (see Supplemental Experimental Procedures for
experimental details). The concentrations of Cm and Cip were
chosen along a single contour of constant growth to keep the
conditions of selection approximately constant for all mutants.
We then measured the full response surface and extracted the
three basis functions that described the effects of the same
two drugs (Cm-Cip) on these mutants (Figures 3A, S3A, and
S3B). The collection of responses represents a broad range of
behaviors, with mutants exhibiting a resistance to Cip and Cm
that varies by an order of magnitude or more (Figure 3A, top).
However, Figure 3B (bottom) demonstrates that these different
behaviors can be unified using a single set of basis functions
common to all mutants, and three scaling parameters (a1, a2,
and a3) specific to each mutant, thus supporting our scaling
hypotheses.
Additionally, we found that this scaling approach was valid for
a wide range of cells across several domains of life, including
E. coli, E. faecalis, and human cancer cells (Figures 3C–3E). In
some cases, we observed statistically significant (as measured
by a3) small changes in drug interaction, for example, from
strongly antagonistic to weakly antagonistic (Figure 3C). In other
cases, scaling unified very different phenotypic behaviors, such
as the synergy and additivity of ampicillin and daptomycin in WT
E. faecalis and a daptomycin-resistant (Dap-C) mutant (Fig-1078 Cell Reports 6, 1073–1084, March 27, 2014 ª2014 The Authorsure 3D; see also Figure 1D). Even more
surprisingly, scaling laws unified the syn-
ergy and antagonism of 17-AAG and gefi-
tinib found in human NSCLC cells and a
gefitinib-resistant mutant (Figure 3E; see
also Figure 1A). Thus, although response
surfaces can sometimes change mark-
edly when resistance is acquired, we
find that the functional forms of the
underlying basis functions are conserved.
These results suggest that the re-
sponse surfaces of drug-resistant cells
are constrained by those of the drug-
sensitive WT cells. If so, one could fully
characterize the response surface of aresistant mutant by estimating with only a few measurements
the scaling parameters a1, a2, and a3, thus eliminating the need
for a labor-intensive sampling of the entire surface. Because
this rescaling procedure requires very few measurements, it
allows one to infer behavior even in unsampled regions of
dosage space (Figure 4, schematic).
Scaling Relations Can Be Used to Rapidly Infer
Response Surfaces of Resistant Mutants
To examine whether scaling relations can be used to predict the
response surfaces of resistant mutants, we first focused on three
clinically relevant bacterial species: S. aureus, E. faecalis, and
E. coli. For S. aureus, we measured the full response surface of
WT and Nor-resistant cells for the drug combination Nor-Cm,
which is antagonistic in WT cells (Figure 5A, left; see also Fig-
ure 1F). Using only five randomly selected data points, we
estimated the scaling parameters and used them to infer mutant
growth in unsampled regions of dosage space. The scaling
parameters reflect slightly increased sensitivity to Cm (a1 > 1)
and increased resistance to Nor (a2 << 1). The antagonism
between drugs is equal to that in WT cells (a3 1; see also Fig-
ure 1F), making this example similar to those previously reported
in E. coli (Figure S3C; Chait et al., 2007).
Next, we compared the responses of a daptomycin-sensitive
strain and three daptomycin-resistant strains of E. faecalis
(Palmer et al., 2011) to combinations of daptomycin and ampi-
cillin (Figures 5B, S4A, and S4B; see also Figure 1D). These
strains were evolved under daptomycin pressure and represent
three distinct evolutionary routes to daptomycin resistance, each
with a unique set of geneticmutations (Palmer et al., 2011). Using
the WT basis functions, we are able to predict the two-drug
response for each mutant by estimating the parameters a1, a2,
and a3. For the ampicillin-daptomycin combination, all three
mutants demonstrate significant resistance to daptomycin
(a1 < 0.02), increased sensitivity to ampicillin (a2 > 1), and a
drug-drug interaction with slightly (a3 = 0.87, Dap-A mutant) or
significantly (a3 = 0.05, Dap-C mutant) decreased synergy (Fig-
ure 5B; see also Figure 3D).We also accurately inferred response
surfaces for combinations of daptomycin and linezolid, an oxa-
zolidinone that is often used to treat infections of the skin as
well as pneumonia (Figures S4C–S4E).
Finally, we tested the scaling hypothesis for two clinically iso-
latedE. colimutants that shareaparticularly commonmechanism
of drug resistance: modification of the drug target (Cohen et al.,
1989) (748k.01; Figures S4F and S4G). Specifically, each strain
exhibited resistance to DNA synthesis inhibitors (fluoroquino-
lones) arising from distinct mutations in the gene (gyrA) encoding
the target topoisomerase (Cohen et al., 1989). In both cases, the
three-parameter scaling provides an excellent prediction of the
response surfaces to Cm and Cip (Figures S4F and S4G), and
allmutantsexhibit little resistance toCm(a11), strong resistance
to Cip (a2 < 0.1), and significantly weaker drug-drug suppression
(a3 < 1) than in theWT. These scaling relationships hold aswell for
multipleE. coli laboratorymutantswith evolved resistance to pro-
tein synthesis inhibitors, including Dox, Ery, and Cm (Figures
S4H–S4K; see also Figures 1B and 1E). We also verified the
scaling relations in a cycloheximide-resistant mutant of the
budding yeast Saccharomyces cerevisiae (Korolev et al., 2012)
exposed to a combination of antifungal agents (Figure S4L).
We next asked whether the scaling hypothesis applies to drug
combinations targeting human cancer cells, which possess
significantly more genetic complexity and redundancy than
microbes. Figure 5C shows the previously discussed gefitinib/
17-AAG combination, where strong antagonism in the parental
NSCLC cells is replaced by synergy in the gefitinib-resistant
(GR6) mutant (Engelman et al., 2007). Remarkably, our rescaling
approach allows us to predict themutant response surface for all
dosage combinations (see also Figure S4N for the same cells
with gefitinib and paclitaxel). We find that there is little resistance
to 17-AAG (a11) but a significant increase in gefitinib resistance
(a2 << 1). In addition, a3 switched signs from positive to negative,
which accounts for the observed phenotypic change from an
antagonistic interaction in the parental cell line to a synergistic
interaction in the mutant (recall Figures 1A and 3F). In this
case, the synergy arises because 17-AAG inhibits HSP90, which
leads to decreased MET protein stability (Xu et al., 2012). The
loss of MET, in turn, sensitizes the previously resistant cells to
gefitinib. In terms of our scaling model, the gefitinib resistance
inverts the drug-drug coupling effect of 17-AAG on gefitinib;
rather than lowering the gefitinib toxicity, as in drug-sensitive
cells, the presence of 17-AAG raises the effective gefitinib
toxicity in mutant cells. These results again demonstrate that
the response surfaces can change markedly following the acti-
vation of a resistance event, whereas the functional forms of
the basis functions are conserved. From a practical perspective,
the scaling approach allows us to rapidly recognize the strong
synergy between 17-AAG and gefitinib in resistant cells (Fig-Ceure 5C), and thus identify a potent therapy despite the fact that
the drugs are antagonistic in drug-sensitive cells. We also
show that the full response surfaces of RAF inhibitor
(PLX4720)-resistant melanoma cells to combinations of antineo-
plastic drugs can be predicted using the same approach
(Figure S4M).
Scaling Relations Can Be Used to Increase Potency
of Drug Combinations Targeting Cancer Stem Cells
Recent research has also focused on the general drug resistance
that appears in cancer stem cells (CSCs), which are believed to
underlie the resurgence of many tumors following initial drug
treatments (Dick, 2009; Gupta et al., 2009; Reya et al., 2001;
Sachlos et al., 2012). Whereas drug-resistant mutants are typi-
cally resistant to a small number of specific drugs, CSCs are,
in general, more drug resistant than the corresponding cancer
cells, and the resistance is not driven by mutations (Dick, 2009;
Gupta et al., 2009; Reya et al., 2001; Sachlos et al., 2012).
Because of their simultaneous resistance to multiple drugs,
CSCs offer an opportunity to test our scaling approach in the
context of general drug resistance.
We first directly measured the effects of two anticancer drugs,
etoposide and fluorouracil (5-FU), on immortalized human
mammary epithelial (HMLE) cells and on matched HMLE popu-
lations enriched for mammary CSCs (Gupta et al., 2009). We
found that the effects of the individual drugs vary significantly
between cell types, with minimum inhibitory concentrations
(MICs) increased by factors of 8.5 for etoposide and 4 for
5-FU in CSCs. However, the effects of this general drug resis-
tance becomemore complicated when the drugs are combined.
For example, we found that treating the HMLE cells with etopo-
side and 5-FU at concentrations of 0.35 mM and 1.5 mM,
respectively, results in growth inhibition of 50% (full growth
surface shown in Figure 5D, left). One would naively expect a
similar inhibition (50%) of CSC growth when the dosages of
each drug are increased to account for the increased MICs of
the drug individually. However, we measured the inhibitory
effects of this naive combination therapy to be only20%,which
is substantially less than expected. Interestingly, our scaling
approach can correctly predict this nonintuitive result with only
a few measurements (Figure 5D). Furthermore, the scaling rela-
tions predict improved therapies. For example, using 8.5 mM
of etoposide alone is correctly predicted to restore growth
inhibition to the previous 50% levels (Figure 5D, right). In this
case, we are also able to decrease the total amount of drug
used, compared with the intuitive therapy. Our prediction
quantitatively captures the increased antagonism between
5-FU and etoposide in CSCs, and indicates that scaling relations
may be applicable to broadly drug-resistant CSCs.
Overall, we see a wide range of a3 values from experiments in
E. coli, E. faecalis, S. aureus, S. cerevisiae, and human cancer
cells (Figure S4O), including a3 < 0 (the interaction has changed
from antagonistic to synergistic or vice versa), 0 < a3 < 1 (the
interaction has decreased in magnitude), and a3 > 1 (the inter-
action has increased in magnitude). In all cases, the mutant
response is reconstructed by rescaling the WT basis functions
with only three scaling parameters (a1, a2, and a3; Figures 5
and S4A–S4N). Therefore, our scaling hypotheses, which arell Reports 6, 1073–1084, March 27, 2014 ª2014 The Authors 1079
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based on conservation of basis functions, hold for all resistant
cells characterized in this study. The scaling also correctly
preserves the interaction (a3 = 1) in a drug-with-itself mock
experiment (Figures S5A–S5D).
Observed Scaling Relationships Are Unlikely toOccur by
Chance
In view of the smoothness of the typical drug-response surfaces,
it is tempting to think that any two surfaces could perhaps be
related by a simple rescaling. Therefore, it is not a priori clear
whether the scaling relationships reported here reflect some
underlying biological similarity between cellular responses or
the scaling relationships are likely to exist between any two-
dimensional response surfaces. To explore this question, we
developed a null model to quantify the probability of observing
our scaling results by chance in a random ensemble of smooth
response surfaces (Supplemental Results; Figures S5E and
S5F). This analysis reveals that the reported experimental scaling
relationships are unlikely to occur by chance (p < 0.1 for at least
32 of 42mutants in the study; Figure S5E).We also find that basis
functions from some drug pairs can be rescaled to fit a large
number of response surfaces, whereas basis functions from
other drug pairs are highly specific to a given drug combination
(Figure S5F). Overall, this analysis suggests that the reported
scaling relationships do not hold for arbitrary response surfaces
and instead represent an unexpected connection between WT
andmutant response surfaces. In addition, the scaling approach
outperforms standard interpolation methods for predicting
growth in unsampled regions of dosage space (Supplemental
Results; Figures S5G–S5J) and is robust to variations in how
the scaling parameters are determined (Supplemental Results;
Figure S5K; Table S7).
Scaling Relations Reflect Species- and Drug-Specific
Relationships
To further explore the limits of the observed scaling relation-
ships, we asked whether basis functions derived from one
specific bacterial type could be rescaled to infer response sur-
faces in other bacterial species. As a consequence of hypothesis
2 of the model, it should be possible to use identical basis func-
tions for closely related species because they have most likelyFigure 5. Rescaling Parameters Predict the Response of Resistant Mu
Predicting the response of resistant mutants to a two-drug combination require
known (see Figure 4).
(A–C) The responses of resistant mutants to each of three two-drug combinations
and 17-AAG in NSCLC cells [HCC827] [C]) are predicted using scaling parame
surements of the mutant’s growth rate. Similarly, the responses of drug-resistant C
with the basis functions from parental cells and five randomly selected measure
mutants, along with SEs, are given by (A) (1.37 ± 0.03, 0.10 ± 0.002; a3 not neede
0.0043 ± 0.0002, 0.22 ± 0.02). Left: heatmap of relative growth rate in WT cells a
Right, large figure: comparison of experiment and prediction for each drug dosag
root mean-squared error (RMSE) of the predicted two-dimensional mutant grow
mutant growth surface is predicted using five randomly selected data points on th
from experiment (top) and prediction (bottom). Black lines show a single contou
spline interpolation (csaps function in MATLAB).
(B–D) The different contour shapes in WT and mutant cells illustrate that drug int
mg/ml for all drugs except 17-AAG (nM), gefitinib (mM), etoposide (mM), and 5-FU
Error bars indicate ±1 SE of the growth rate estimate (see Supplemental Results
Ceevolved similar strategies to cope with chemical stressors. To
test this idea, we rescaled the WT basis functions measured
for E. coli (strain k01.48) exposed to Cm and Cip in an attempt
to describe the Cm-Cip response surface in mutants from other
bacterial strains. We found that scaled versions of the k01.48
Cm-Cip basis provide an excellent description of drug-resistant
mutants from the same strain (Cohen et al., 1989) (k01.48, Fig-
ure 6A, red). However, using the same basis functions yields
increasingly poor predictions for mutants of more distant
E. coli strains (Figure 6A, blue) as well as for cells of distantly
related bacteria (E. faecalis, Figure 6A, black; S. aureus, Fig-
ure 6A, green). Our results suggest that the scaling relationships
may apply across species of closely related organisms, but in
general they cannot be used to unify the drug response of distant
species.
Similarly, we asked whether the basis functions describing
one drug pair could be rescaled to describe the response surface
of a different drug pair. For this purpose, we used the basis func-
tions from the Cm-Cip response surface (E. coli [BW25113]) to
rescale the response surfaces from other drug pairs in the
same strain (Figure 6B). We found that the basis functions asso-
ciated with Cm-Cip provide an excellent model for the response
to Cm-ofloxacin (Cm-Ofl), a drug pair with similar modes of
action. The same basis also provides a good model for some
other drug pairs, such as Cm-lincomycin (Cm-Linc) and Dox-Ofl,
whereas other drug pairs, including Cm-trimethoprim (Cm-Tmp)
and Ery-Tmp, cannot be well described with the Cm-Cip basis.
Interestingly, the shapes of some sets of basis functions are
similar, especially when the drugs have similar modes of action.
These basis functions may therefore be used to complement
existing strategies (Yeh et al., 2006) for functionally classifying
drugs because our results indicate that they encode drug-
specific information (see also Table S6).
DISCUSSION
We have experimentally shown that the two-drug responses of
sensitive and resistant cells share common features unified by
simple but general scaling relations. We tested these scaling
relations using a broad collection of drugs, including traditional
classes of antibiotics (inhibitors of protein synthesis, DNAtants to Drug Combinations in Unsampled Regions of Dosage Space
s estimation of only three scaling parameters if the WT two-drug response is
(Cm-Nor in S. aureus [A], ampicillin-daptomycin in E. faecalis [B], and gefitinib
ters estimated with the WT basis functions and five randomly selected mea-
SCs to etoposide and 5-FU are predicted using scaling parameters estimated
ments of the mutant’s growth rate. The parameters (a1, a2, a3) describing the
d), (B) (0.88 ± 0.02, 0.017 ± 0.0005, 0.53 ± 0.06), and (C) (a1, a2, a3 = 0.9 ± 0.05,
nd relative growth rates for five randomly chosen dosages in the mutant cells.
e in the mutant cells. Error bars indicate ±SE of prediction. Inset: histograms of
th surfaces constructed from 2,500 independent trials. In each trial, the entire
e mutant two-drug surface. Right: heatmaps of relative growth rate for mutant
r of constant growth estimated by smoothing the growth surface using cubic
eractions have changed (see also Figures 1 and S1). Drug concentrations are
(mM).
). See also Figure S4.
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A B Figure 6. Scaling Relations Hold across
Related Species or Drug Classes
(A) The basis functions for Cm and Cip in drug-
sensitive E. coli (k01.48) are rescaled to fit Cm-Cip
response surfaces measured in drug-resistant
mutants from the same strain (red) as well as
mutants from E. coli BW25113 (blue), E. faecalis
(black), and S. aureus (green). Deviation from
perfect model is defined as 1  R2, where the
coefficient of determination, R2, is defined as R2 =
1 SSerr / SStot (where SSerr is the residual sum of
squares between model and data, and SStot is the
total sum of squares, which is proportional to the
variance of the experimental measurements). A
schematic phylogenetic tree is plotted below the
horizontal axis.
(B) The basis functions for Cm and Cip in drug-
sensitive E. coli (BW25113) are rescaled to
fit response surfaces to other drug pairs in the
same strain. Deviation from perfect model is
defined as in (A).
See also Figure S5 for more detailed statistical
analysis.synthesis, cell wall synthesis, and folic acid synthesis), clinically
relevant antibiotics (linezolid and daptomycin), and drugs that
induce a general stress response (salicylate). We also used
both classic chemotherapy drugs (e.g., alkylating agents, micro-
tubule inhibitors, and topoisomerase inhibitors) and targeted
therapies. We demonstrated the predictive power of these
scaling relations in a wide range of mutants exhibiting many
resistance mechanisms, including drug-efflux-mediated resis-
tance, target modification (e.g., fluoroquinolone-resistant
E. coli; Figures S4F and S4G), pathway reactivation (gefitinib-
resistant mutant, as shown in Figures 1A, 3E, and 5C;
PLX4720-resistant A375, as shown in Figure S4M), and dediffer-
entiation (CSCs; Figures 6A and 6B). The scaling relations, anal-
ogously to phenomenological laws, are not directly noticeable in
two-dimensional response surfaces. However, when the sur-
faces are decomposed into three basis functions, the underlying
symmetry is clear: the shapes of these functions do not change
when resistance is acquired. Previous work suggested that inter-
actions between inhibitors of a biochemical network reflect the
underlying network topology (Leha´r et al., 2007). In our model,
these network properties seem to manifest themselves as
two-drug toxicity functions with specific functional forms (Sup-
plemental Results). Our primary experimental result is that,
surprisingly, these shapes are not fundamentally altered when
cells become resistant, even when the response surfaces of
drug-sensitive and -resistant cells differ dramatically.
From a molecular perspective, these scaling properties may
arise because resistance is conferred by relatively small genetic
changes, and not by any major rewiring of intracellular networks
that govern the global response to drugs. Therefore, the mutant
response is inherently constrained by that of the drug-sensitive
parental cells. These scaling relations are evident in genetically
similar cells, but they break down when applied across evolu-
tionary distant species. Overall, we found these relationships
between drug-sensitive and -resistant cells to be robust within
many organisms, both prokaryotic and eukaryotic, and within
many classes of drugs. Therefore, scaling relationships may1082 Cell Reports 6, 1073–1084, March 27, 2014 ª2014 The Authorsreduce the complexity of drug-resistance studies by unifying
the responses of drug-resistant mutants with those of drug-
sensitive cells even before specific biochemical mechanisms
have been elucidated.
EXPERIMENTAL PROCEDURES
Cell Lines, Strains, and Reagents
Bacteria
The bacterial strains used in this study are listed in Table S1.
Mammalian Cells
HCC827 parental (WT) and gefitinib-resistant (GR6) cells, the latter of which
were evolved by stepwise selection in increasing concentrations of gefitinib,
were obtained from J. Engelman (Massachusetts General Hospital) and grown
in RPMI with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
HMLE cells stably expressing lentiviral short hairpin RNAs (shRNAs) against
GFP (control) and E-Cadherin were obtained from P. Gupta (Whitehead Insti-
tute for Biomedical Research) and grown in media consisting of equal parts of
(1) complete MEGM media (Lonza) and (2) Dulbecco’s modified Eagle’s
medium with 10% FBS and 1% penicillin/streptomycin (Gupta et al., 2009).
A375 parental (WT) cells were obtained from ATCC and grown in RPMI with
10% FBS and 1% penicillin/streptomycin. PLX4720-resistant A375 cells
were engineered by stably overexpressing the kinase C-RAF, which can confer
resistance to PLX4720 by overriding B-RAF dependence (Montagut et al.,
2008). C-RAF-expressing lentiviruses were produced as previously described
(Johannessen et al., 2010; Wood et al., 2012). A375 parental cells were
infected at a 1:10 dilution of virus in six-well plates in the presence of 7.5 mg/ml
polybrene and centrifuged at 1,200 g for 1 hr at 37C. At 24 hr after infection,
blasticidin (10 mg/ml) was added and cells were selected for 72 hr, after which
the blasticidin was removed and growth inhibition assays were performed.
Drugs
Drug solutions were made from solid stocks (Table S2). All antibiotic stock
solutions were stored in the dark at 20C in single-use daily aliquots. All
drugs were thawed and diluted in sterilized media for experimental use.
Growth-Inhibition Assays
Growth Assay for Bacteria
We inoculated media (LB for E. coli, TSB for S. aureus, and BHI for E. faecalis)
from a single colony and grew the cells overnight (12 hr at 30Cwith shaking at
200 rpm for E. coli and S. aureus; no shaking for E. faecalis). Following
overnight growth, stationary phase cells were diluted (5,000-fold for E. coli
and S. aureus; 1,000-fold for E. faecalis) in media. Following the initial
dilution, S. aureus and E. faecalis were grown in drug-free media for 1 hr prior
to addition of drugs and transfer to 96-well plates. We transferred E. coli to
96-well plates (round bottomed, polystyrene; Corning) immediately following
dilution. For each experiment, we set up a two-dimensional matrix of one or
two drug combinations in each of four 96-well plates (165–190 ml media per
well). For the remainder of the experiment after the addition of drugs
(10–12 hr), cells were grown at 30C (with shaking at 1,000 rpm on four
identical vibrating plate shakers for E. coli; no shaking for E. faecalis). A600
(absorbance at 600 nm, proportional to optical density) was measured at
15–25 min intervals (with one exception; see below) using a Wallac Victor-2
1420 Multilabel Counter (PerkinElmer) combined with an automated robotic
system (Twister II; Caliper Life Sciences) to transfer plates between the
shakers and the reader. Growth rates in bacteria were determined by fitting
background-subtracted growth curves (A600 versus time) in early exponential
phase (0.01 < A600 < 0.1) to an exponential function (MATLAB 7.6.0 curve-
fitting toolbox; MathWorks). For S. aureus with Nor-Cm (Figure 5), effective
exponential growth rates were estimated using background-subtracted A600
measurements at times t = 2 hr and t = 6 hr. True exponential growth curves
are therefore not required for this particular assay, which is instead similar to
traditional viability assays that compare cell numbers at the end of the
experiment (see below). Growth rates were normalized by the growth of cells
in the absence of drugs. Error bars, unless otherwise noted, are taken to
represent ±1 SE of the fitted parameter.
Growth Assay for Mammalian Cells
Cells were trypsinized, counted, and seeded into 96-well plates at 2,500 cells
per well. DMSO or concentrated dilutions of indicated drugs (in DMSO) were
added to the cells (1:1,000 in standard media) 24 hr later in otrder to yield
the indicated final drug concentrations. Cell viability was measured 4 days
after drug addition using the Cell Titer Glo luminescent viability assay
(Promega). Viability was calculated as the percentage of control (untreated
cells) after background subtraction. Three replicates were performed for
each drug/concentration.
Evolved Drug-Resistant Mutants in E. coli and S. aureus
Drug-resistant E. coli mutants were evolved under the conditions listed in
Table S3. S. aureus Nor-resistant mutants were isolated on Tryptic Soy Agar
(BD Biosciences) plates containing 4 mg/ml Nor, followed by spreading of
overnight culture of Newman strain.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, five figures, and seven tables and can be found
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